Document

Filter documents

pdf icon

FSRH CEU Statement: Response to new reports of link between COC and Glaucoma (November 2013)

File size: 55kb | Date: 1 November 2013 | Clinical Statements - PDF

Following a presentation at the annual meeting of the American Academy of Ophthalmology a number of media reports have reported a possible link between use of combined oral contraception (COC) and glaucoma. There is limited data investigating combined hormonal contraceptives on glaucoma. One cohort study suggested that 5 or more years of COC use was associated with a 25% increase in the risk of glaucoma. Two UK cohort studies did not find consistent evidence of an increased risk.

pdf icon

FSRH CEU Statement: Strengthening of Warnings about use of Dianette and other brands of co-cyprindiol (June 2013)

File size: 58kb | Date: 1 June 2013 | Clinical Statements - PDF

Following a recent safety review, a letter has been issued to healthcare professionals from the manufacturers of Dianette® and other cyproterone acetate 2 mg/ ethinylestradiol 35 mcg (co-cyprindiol) products. The review by the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) followed concerns about the risk of thrombosis associated with co-cyprindiol. With the agreement of the EMA and Medicines and Healthcare products Regulatory Authority (MHRA), a letter has been issued to raise awareness of the thrombosis risks and the outcome of the review.

pdf icon

FSRH New Product Review: Sayana Press® (June 2013)

File size: 140kb | Date: 1 June 2013 | New Product Reviews - PDF

Injectable progestogen-only contraception is a popular and effective method of contraception and until now, in the UK has largely been administered as Depo-Provera®, an intramuscular (IM) injection of 150mg medroxyprogesterone acetate (DMPA).

pdf icon

FSRH New Product Review: Estradiol/Nomegestrol Combined Pill, Zoely© (May 2013)

File size: 269kb | Date: 1 May 2013 | New Product Reviews - PDF

The combined oral contraceptive Zoely® (Merck, Sharp, and Dohme Limited) has been licensed in Europe since 2011 and will be available in the UK from May 2013. Zoely will be the second UK combined oral contraceptive (COC) to contain estradiol and to be formulated as an extended regimen since the introduction of Qlaira® (Bayer plc.)

pdf icon

FSRH Clinical Standards All Service Standards Jan 2013

File size: 7901kb | Date: 1 January 2013 | Clinical Standards - PDF

These Standards are recommended for organisations providing contraceptive/sexual and reproductive health (SRH) services, including pregnancy planning, pregnancy choices, abortion, prevention and treatment of sexually transmitted infections (STIs), as well as sexual wellbeing and health promotion.

pdf icon

Statement from the FSRH Clinical Standards Committee, the Clinical Effectiveness Committee and the Associate Members’ Working Group on the prescription, administration or supply of Contraceptive Medicines for use outside the terms of their licences Dec 09

File size: 65kb | Date: 1 December 2009 | Clinical Standards - PDF

The above committees have agreed that Clinical Effectiveness Unit Guidance on use of contraceptives is guidance on “common practice” and “current practice” in the use of these medicines and devices. Therefore it is recommended that it may not be necessary for clinicians to document every occasion when a contraceptive preparation is prescribed outside the product licence if such use falls within current guidance issued by the Faculty’s Clinical Effectiveness Unit.